Display options
Cite
Iqbal MS, Shaikh G, Chatterjee S, et al. Maintenance therapy with trastuzumab in her2 positive metastatic parotid ductal adenocarcinoma. Case Rep Oncol Med. 2014;2014:162534doi: 10.1155/2014/162534.
Iqbal, M. S., Shaikh, G., Chatterjee, S., Cocks, H., & Kovarik, J. (2014). Maintenance therapy with trastuzumab in her2 positive metastatic parotid ductal adenocarcinoma. Case reports in oncological medicine, 2014162534. https://doi.org/10.1155/2014/162534
Iqbal, Muhammad Shahid, et al. "Maintenance therapy with trastuzumab in her2 positive metastatic parotid ductal adenocarcinoma." Case reports in oncological medicine vol. 2014 (2014): 162534. doi: https://doi.org/10.1155/2014/162534
Iqbal MS, Shaikh G, Chatterjee S, Cocks H, Kovarik J. Maintenance therapy with trastuzumab in her2 positive metastatic parotid ductal adenocarcinoma. Case Rep Oncol Med. 2014;2014:162534. doi: 10.1155/2014/162534. Epub 2014 Jul 17. PMID: 25136467; PMCID: PMC4127246.
Copy Download .nbib Format: NLM
Share it on

Case Rep Oncol Med. 2014;2014:162534. doi: 10.1155/2014/162534. Epub 2014 Jul 17.

Maintenance therapy with trastuzumab in her2 positive metastatic parotid ductal adenocarcinoma.

Case reports in oncological medicine

Muhammad Shahid Iqbal, Ghazia Shaikh, Sanjoy Chatterjee, Helen Cocks, Josef Kovarik

Affiliations

  1. Department of Clinical Oncology, Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne NE7 7DN, UK.
  2. Department of Oncology, Tata Medical Centre, Kolkata 700 156, India.
  3. Department of Otolaryngology, Sunderland Royal Hospital, Kayll Road, Sunderland SR4 7TP, UK.

PMID: 25136467 PMCID: PMC4127246 DOI: 10.1155/2014/162534

Abstract

Salivary ductal carcinomas (SDCs) are extremely rare and aggressive malignancies, accounting for approximately 6% of all salivary gland malignancies. One distinct feature is their resemblance to ductal carcinomas of breast. A significant percentage of SDCs overexpress Her2 and the use of targeted therapy with trastuzumab can be considered in these patients. We report a rare case of long term disease control with trastuzumab in Her2 positive metastatic parotid ductal carcinoma. Our case also highlights that isolated brain metastasis should be managed aggressively to allow optimal local control when systemic disease is under remission with trastuzumab. We have also reviewed the published literature on the use of trastuzumab in SDCs.

References

  1. Lancet. 2010 Aug 28;376(9742):687-97 - PubMed
  2. Future Oncol. 2013 Nov;9(11):1653-64 - PubMed
  3. Clin Cancer Res. 2013 Jan 15;19(2):480-90 - PubMed
  4. J Clin Pathol. 2003 Dec;56(12):914-8 - PubMed
  5. Otolaryngol Head Neck Surg. 1985 Apr;93(2):146-7 - PubMed
  6. Int J Cancer. 1999 Apr 20;84(2):129-34 - PubMed
  7. Oral Oncol. 2005 Jan;41(1):97-8 - PubMed
  8. J Clin Oncol. 2007 Sep 1;25(25):3978-84 - PubMed
  9. Head Neck. 2008 May;30(5):680-3 - PubMed
  10. Clin Cancer Res. 2007 Mar 15;13(6):1648-55 - PubMed
  11. Curr Med Chem Anticancer Agents. 2004 Nov;4(6):543-51 - PubMed
  12. Arch Otolaryngol Head Neck Surg. 1991 Mar;117(3):307-15 - PubMed
  13. N Engl J Med. 2001 Mar 15;344(11):783-92 - PubMed
  14. Avicenna J Med. 2012 Jul;2(3):71-73 - PubMed
  15. Case Rep Oncol. 2013 Sep 10;6(3):450-5 - PubMed
  16. Med Oncol. 2012 Jun;29(2):704-6 - PubMed
  17. Oral Dis. 2002 Sep;8(5):229-40 - PubMed
  18. Otolaryngol Head Neck Surg. 2003 Dec;129(6):720-5 - PubMed
  19. Oral Oncol. 2003 Oct;39(7):724-7 - PubMed
  20. Arch Pathol Lab Med. 2009 Nov;133(11):1763-74 - PubMed
  21. Oncologist. 2013;18(3):294-300 - PubMed
  22. Head Neck Oncol. 2010 May 26;2:12 - PubMed
  23. J Laryngol Otol. 2009 Feb;123(2):250-2 - PubMed

Publication Types